# FDA and EMA Approve Datroway and Trodelvy for Triple-Negative Breast Cancer in Q2 2026

> fda · REPORTED · 2026-07-15

Both the FDA and EMA approved datopotamab deruxtecan (Datroway) and sacituzumab govitecan (Trodelvy) for the treatment of triple-negative breast cancer in Q2 2026, as part of a broader wave of 32 new or expanded oncology approvals that included five entirely new oncology agents.

About FDA / Daiichi Sankyo and AstraZeneca (Datroway) and Gilead (Trodelvy): Daiichi Sankyo and AstraZeneca co-developed Datroway, a TROP2-directed antibody-drug conjugate, while Gilead's Trodelvy is a Trop-2-targeted ADC; both serve patients with difficult-to-treat triple-negative breast cancer.

- Company: FDA / Daiichi Sankyo and AstraZeneca (Datroway) and Gilead (Trodelvy)
- Sector: oncology
- Primary source: https://www.aptitudehealth.com/oncology-news/fda-and-ema-oncology-drug-approvals-in-q2-2026-included-several-new-options-for-breast-cancer-treatment/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.